申请人:Seo Ryushi
公开号:US20090036421A1
公开(公告)日:2009-02-05
[Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT
2B
receptor and 5-HT
7
receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).
[Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT
2B
receptor and 5-HT
7
receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT
2B
receptor and 5-HT
7
receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).
[问题] 提供一种可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病,特别是治疗肠易激综合征(IBS)的化合物。
[解决方案] 发现一种吡咯衍生物,在其3位具有胍基甲酰基基团或酰胺基团作为取代基团,或其药学上可接受的盐,具有对5-HT2B受体和5-HT7受体的强拮抗作用。此外,与仅使用对其中一种受体选择性拮抗剂相比,具有对两种受体拮抗活性的本发明化合物显示出良好的药理作用。基于上述,本发明化合物对于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病,特别是治疗肠易激综合征(IBS)是有用的。